# Phase I Study of IPI-504 and Docetaxel in Patients With Advanced Solid Tumors

> **NCT00606814** · PHASE1 · COMPLETED · sponsor: **Infinity Pharmaceuticals, Inc.** · enrollment: 60 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** IPI-504, docetaxel

## Key facts

- **NCT ID:** NCT00606814
- **Lead sponsor:** Infinity Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12
- **Primary completion:** 2011-05
- **Final completion:** 2011-12
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2012-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00606814

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00606814, "Phase I Study of IPI-504 and Docetaxel in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00606814. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*